San Diego biotech Neomorph, which is developing a protein degradation-based platform to enable novel drug development for hard-to-treat diseases, has raised $109 million in a Series A round of venture ...
SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...
The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen. Collaboration leverages Neomorph's leading molecular glue discovery platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback